Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo purchased 30,861 shares of the company’s stock in a transaction that occurred on Thursday, November 23rd. The stock was bought at an average price of GBX 9 ($0.12) per share, with a total value of £2,777.49 ($3,653.15).

Lorenzo Tallarigo also recently made the following trade(s):

  • On Monday, October 23rd, Lorenzo Tallarigo purchased 30,436 shares of Oxford BioMedica plc stock. The stock was bought at an average price of GBX 9 ($0.12) per share, with a total value of £2,739.24 ($3,602.84).
  • On Friday, September 22nd, Lorenzo Tallarigo purchased 29,685 shares of Oxford BioMedica plc stock. The stock was bought at an average price of GBX 9 ($0.12) per share, with a total value of £2,671.65 ($3,513.94).

Shares of Oxford BioMedica plc (LON:OXB) opened at GBX 8.55 ($0.11) on Friday. Oxford BioMedica plc has a 1-year low of GBX 3.31 ($0.04) and a 1-year high of GBX 11.25 ($0.15).

COPYRIGHT VIOLATION WARNING: “Oxford BioMedica plc (OXB) Insider Lorenzo Tallarigo Buys 30,861 Shares of Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/11/24/oxford-biomedica-plc-oxb-insider-lorenzo-tallarigo-buys-30861-shares-of-stock.html.

OXB has been the subject of several recent research reports. N+1 Singer lifted their price target on Oxford BioMedica plc from GBX 8.70 ($0.11) to GBX 10.20 ($0.13) and gave the stock a “hold” rating in a research report on Thursday, August 31st. Peel Hunt restated a “buy” rating and set a GBX 13 ($0.17) target price on shares of Oxford BioMedica plc in a research report on Tuesday, October 31st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a GBX 13 ($0.17) price target on shares of Oxford BioMedica plc in a report on Thursday, August 31st.

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Insider Buying and Selling by Quarter for Oxford BioMedica plc (LON:OXB)

Receive News & Stock Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related stocks with our FREE daily email newsletter.